Evidence map›Paper›PMID 41065719›Full record

ArticleProtein engineering, design & selection : PEDS2025

Design of a ligand-dependent fluorescent biosensor, based on an engineered lipocalin (anticalin), for the sensitive detection of the Alzheimer β-amyloid peptide.

Anna Feuerbach, Arne Skerra

Abstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anna FeuerbachLehrstuhl für Biologische Chemie, Technische Universität München, Emil-Erlenmeyer-Forum 5, 85354 Freising, Germany.
Arne SkerraLehrstuhl für Biologische Chemie, Technische Universität München, Emil-Erlenmeyer-Forum 5, 85354 Freising, Germany.ORCID 0000-0002-5717-498X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Edited by: Robert E. Campbell Based on the Anticalin H1GA which tightly binds Aβ40 and Aβ42 peptides - both established biomarkers of Alzheimer's disease - we describe the design of a protein-dye conjugate as analytical reagent that shows strongly elevated fluorescence upon Aβ binding. An unpaired Cys residue was introduced at seven positions within the four loop segments that shape the ligand pocket of the engineered lipocalin. Five of these mutants were purified in the monomeric state and allowed the site-specific conjugation with IANBD amide as a solvatochromic fluorophore. Three conjugates showed ligand-dependent fluorescence and one of these, derived from H1GA(D45C), exhibited sixfold higher emission at 546 nm upon complex formation with the peptide while revealing a low KD value of 1.2 ± 0.8 nM, even in the presence of 5% (w/v) albumin. This NBD-conjugated Anticalin offers a novel biosensor with potential for the detection of Aβ peptides in biochemical assays or human body fluid samples.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiosensing TechniquesFluorescent DyesLipocalinsProtein EngineeringHumansLigandsAmyloid beta-PeptidesFluorescent DyesLigandsLipocalinsA-beta peptideAnticalindiagnosticsneurodegenerationprotein engineering

Identifiers

PMID41065719
PMCPMC12626432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.